View ValuationBioArctic 향후 성장Future 기준 점검 6/6BioArctic (는) 각각 연간 53.3% 및 28.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 51.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 35.8% 로 예상됩니다.핵심 정보53.3%이익 성장률51.24%EPS 성장률Biotechs 이익 성장34.3%매출 성장률28.7%향후 자기자본이익률35.85%애널리스트 커버리지Low마지막 업데이트22 May 2026최근 향후 성장 업데이트분석 기사 • 6hBioArctic AB (publ) Just Reported A Surprise Profit, And Analysts Lifted Their EstimatesAs you might know, BioArctic AB (publ) ( STO:BIOA B ) recently reported its quarterly numbers. Revenues of 66% beat...Major Estimate Revision • May 18Consensus EPS estimates increase by 344%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from kr1.20b to kr1.25b. EPS estimate increased from kr0.66 to kr2.93 per share. Net income forecast to shrink 75% next year vs 9.0% growth forecast for Biotechs industry in Sweden . Consensus price target of kr301 unchanged from last update. Share price was steady at kr324 over the past week.Major Estimate Revision • Feb 25Consensus EPS estimates fall by 72%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from kr1.13b to kr1.23b. EPS estimate fell from kr2.32 to kr0.66 per share. Net income forecast to shrink 72% next year vs 11% growth forecast for Biotechs industry in Sweden . Consensus price target broadly unchanged at kr304. Share price fell 13% to kr318 over the past week.분석 기사 • Nov 16BioArctic AB (publ) (STO:BIOA B) Just Released Its Third-Quarter Earnings: Here's What Analysts ThinkIt's been a pretty great week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with its shares surging 12% to kr295...Major Estimate Revision • Sep 08Consensus EPS estimates fall by 13%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from kr1.94b to kr2.00b. EPS estimate fell from kr13.71 to kr11.90 per share. Net income forecast to shrink 36% next year vs 19% growth forecast for Biotechs industry in Sweden . Consensus price target up from kr286 to kr293. Share price fell 6.1% to kr290 over the past week.Price Target Changed • Sep 02Price target increased by 8.8% to kr311Up from kr286, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of kr317. Stock is up 92% over the past year. The company is forecast to post earnings per share of kr12.81 next year compared to a net loss per share of kr2.00 last year.모든 업데이트 보기Recent updates분석 기사 • 6hBioArctic AB (publ) Just Reported A Surprise Profit, And Analysts Lifted Their EstimatesAs you might know, BioArctic AB (publ) ( STO:BIOA B ) recently reported its quarterly numbers. Revenues of 66% beat...Upcoming Dividend • May 22Upcoming dividend of kr2.00 per shareEligible shareholders must have bought the stock before 29 May 2026. Payment date: 04 June 2026. Payout ratio is on the higher end at 83%, however this is supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Swedish dividend payers (4.1%). Lower than average of industry peers (2.2%).New Risk • May 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 19% Last year net profit margin: 59% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.속보 • May 20FDA Pushes Leqembi Iqlik Decision to August 2026 Keeping BioArctic in Global SpotlightThe FDA has extended its review of the supplemental Biologics License Application for Leqembi Iqlik, a once-weekly subcutaneous formulation for early Alzheimer's disease, pushing the PDUFA date to 24 August 2026 after requesting additional information classified as a major amendment. Regulators have not raised concerns about the approvability of Leqembi Iqlik, while Leqembi is already authorized in more than 50 countries and Eisai and BioArctic are preparing for joint commercialization of the subcutaneous product in the Nordic region. Eisai’s Leqembi sales in its 2025 fiscal year surpassed €500m, triggering a €20m milestone payment to BioArctic. Long-term and real-world data suggest patients stay on treatment for extended periods, with disease-slowing effects observed for up to four years, even as Sweden’s NT Council has denied reimbursement and other submissions progress in the EU, US and China. The FDA review extension introduces a longer timeline for the new formulation, but the breadth of existing approvals and ongoing global submissions keep Leqembi central to BioArctic’s commercial story. Investors may want to pay close attention to future regulatory and reimbursement decisions, since they directly affect the pace and scale of potential royalty streams and milestone payments to BioArctic.Major Estimate Revision • May 18Consensus EPS estimates increase by 344%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from kr1.20b to kr1.25b. EPS estimate increased from kr0.66 to kr2.93 per share. Net income forecast to shrink 75% next year vs 9.0% growth forecast for Biotechs industry in Sweden . Consensus price target of kr301 unchanged from last update. Share price was steady at kr324 over the past week.내러티브 업데이트 • May 18BIOA B: Future Returns Will Depend On High NLRP3 Execution RiskAnalysts kept their SEK 240.00 price target for BioArctic unchanged, with slightly lower discount rate and profit margin assumptions, and a higher future P/E multiple that reflects refined views on the stock's risk profile and earnings power. Analyst Commentary Recent research on BioArctic has centered on how changing assumptions around risk, profitability, and long term earnings power feed into valuation.Reported Earnings • Apr 26Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: kr11.55 (up from kr2.00 loss in FY 2024). Revenue: kr2.00b (up kr1.74b from FY 2024). Net income: kr1.02b (up kr1.20b from FY 2024). Profit margin: 51% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.내러티브 업데이트 • Apr 22BIOA B: Future Returns Will Depend On High NLRP3 Execution RiskAnalysts have kept their SEK 240.0 price target for BioArctic unchanged, explaining the steady view by slightly adjusting discount rate, revenue growth, profit margin and future P/E assumptions, while balancing higher perceived risk with ongoing optimism around the broader NLRP3 and cardiovascular opportunity highlighted in recent peer research. Analyst Commentary Research coverage around NLRP3-targeted therapies has been active, with several firms updating their views and price targets on peers such as BioAge Labs.내러티브 업데이트 • Apr 08BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced OutlookThe analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.공시 • Mar 28Bioarctic AB Announces Declining of Re-Election by Pär Gellerfors as Board MemberBioArctic AB at the Annual General Meeting to be held on May 28, 2026 announced that Board member Pär Gellerfors has declined re-election.내러티브 업데이트 • Mar 25BIOA B: Future Earnings Will Depend On High China Access RiskAnalysts have nudged their fair value estimate for BioArctic to SEK240 from SEK236. This reflects updated assumptions around revenue contraction, profitability and a higher future P/E multiple, while keeping the discount rate broadly similar.내러티브 업데이트 • Mar 10BIOA B: China Alzheimer’s Access And Delivery Shift Will Drive Future UpsideAnalysts are keeping their SEK 367.0 price target for BioArctic broadly unchanged, with only modest tweaks to underlying assumptions. They highlight parallels with recent bullish Street research on early stage biotech names that are seeing renewed interest around differentiated clinical assets.Major Estimate Revision • Feb 25Consensus EPS estimates fall by 72%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from kr1.13b to kr1.23b. EPS estimate fell from kr2.32 to kr0.66 per share. Net income forecast to shrink 72% next year vs 11% growth forecast for Biotechs industry in Sweden . Consensus price target broadly unchanged at kr304. Share price fell 13% to kr318 over the past week.내러티브 업데이트 • Feb 24BIOA B: Peer Re-Rating And China Alzheimer’s Momentum Will Reframe UpsideAnalysts have raised their BioArctic fair value estimate from SEK353 to SEK367 as they factor in updated views on revenue growth, margins, discount rate and a higher future P/E assumption aligned with recent bullish Street research on comparable biotech names. Analyst Commentary Recent Street research on comparable biotech names has turned more optimistic, with bullish analysts revisiting their models and price targets in light of updated clinical views and perceived market potential.Reported Earnings • Feb 19Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: kr11.55 (up from kr2.00 loss in FY 2024). Revenue: kr2.00b (up kr1.74b from FY 2024). Net income: kr1.02b (up kr1.20b from FY 2024). Profit margin: 51% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.공시 • Feb 18+ 1 more updateBioArctic AB (publ) to Report Q3, 2026 Results on Nov 25, 2026BioArctic AB (publ) announced that they will report Q3, 2026 results on Nov 25, 2026공시 • Feb 11BioArctic AB (publ) to Report Q4, 2025 Results on Feb 18, 2026BioArctic AB (publ) announced that they will report Q4, 2025 results at 8:00 AM, Central European Standard Time on Feb 18, 2026공시 • Feb 10Bioarctic AB (Publ) for Subcutaneous Formulation of Leqembi Designated for Priority Review in ChinaBioArctic AB's (publ) partner Eisai announced that the Biologics License Application (BLA) for the treatment of early Alzheimer's disease with Leqembi (lecanemab), using a subcutaneous autoinjector (SC-AI), has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The BLA for the subcutaneous formulation was accepted for review by the NMPA in January 2026. The Priority Review and Approval Procedure has been implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened. If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration every two weeks in a hospital setting. The potential approval of SC-AI would expand the option for patients and care partners to receive Leqembi treatment at home. Eisai estimates that in 2024 there were 17 million patients with Mild Cognitive Impairment (MCI) or mild disease due to Alzheimer's disease in China, a number that is expected to rise as the population ages. Leqembi was launched in China in June 2024 and is available to the private market. Furthermore, Leqembi has been included in the newly introduced "Commercial Insurance Innovative Drug List" which took effect in January 2026, under new Chinese government policies that support the development of and access to innovative medicines. Based on the Commercial Insurance Innovative Drug List, commercial insurance companies will develop insurance products covering Leqembi. Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lann felt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug list", recently introduced by the National Healthcare Security Administration (NHSA) of China. In January 2026, Eisai's supplemental Biologics License Application regarding a subcutaneous starting dose with Leqembi Iqlik was granted Priority Review by the US FDA with a May 24, 2026, PDUFA date. Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2026, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington, Sweden.내러티브 업데이트 • Feb 09BIOA B: Future Earnings Will Depend On Risky China Insurance AccessAnalysts have raised their fair value estimate for BioArctic from SEK 230 to SEK 236, citing updated assumptions regarding discount rates, revenue growth, profit margins and a slightly higher future P/E multiple. Analyst Commentary Recent analyst work on comparable neurology and biotech names highlights how sensitive valuations can be to small shifts in assumptions around discount rates, revenue build, profitability and terminal P/E multiples.내러티브 업데이트 • Jan 25BIOA B: Future Earnings Will Rely On Risky China Alzheimer AccessAnalysts now keep their price target for BioArctic at SEK 230.00, with small adjustments to the discount rate, revenue growth assumptions and future P/E outlook. This reflects only minor changes to their overall view of the company’s risk and profitability profile.New Risk • Jan 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 68% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risk Significant insider selling over the past 3 months (kr54m sold).내러티브 업데이트 • Jan 09BIOA B: Future Earnings Will Depend On Risky Alzheimer Access RolloutAnalysts have maintained their fair value estimate for BioArctic at SEK 230.00. They have, however, adjusted assumptions related to the discount rate, revenue trends, profit margins, and future P/E to reflect updated views on the company’s risk profile and earnings potential.내러티브 업데이트 • Dec 26BIOA B Future Long Term Margin Upside Will Not Offset Demand RisksAnalysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.Recent Insider Transactions • Dec 22Co-Founder recently sold kr54m worth of stockOn the 18th of December, Lars Lannfelt sold around 174k shares on-market at roughly kr310 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Lars' only on-market trade for the last 12 months.내러티브 업데이트 • Dec 12BIOA B: Future Revenue Weakness Will Outweigh Expanding Alzheimer’s Market ApprovalAnalysts have reduced their price target on BioArctic from SEK 280 to SEK 230. This reflects a more cautious outlook on future revenue growth despite improved profitability expectations and a slightly higher discount rate.Recent Insider Transactions • Dec 07VP & Head of CMC recently sold kr320k worth of stockOn the 4th of December, Mikael Moge sold around 1k shares on-market at roughly kr320 per share. This transaction amounted to 8.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr2.2m more than they bought in the last 12 months.공시 • Nov 19BioArctic AB's (publ) Partner Eisai to Present the Latest Findings on Lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease ConferenceBioArctic AB's (publ) partner Eisai will present the latest findings on lecanemab (Leqembi®?) at the Clinical Trials on Alzheimer's Disease (CTAD) conference, being held in San Diego December 1-4. Presentations will include data on long-term treatment and estimated time savings over 10 years, as well as safety and potential benefits of subcutaneous administration of lecanemab for initiation dosing. In addition, data on the effects of lecanemab on soluble amyloid-beta (Ab) protofibrils and insights from real-world clinical practice studies, including the US ALZ-NET registry, will also be presented. Key oral presentations: Continued treatment: On Tuesday, Dec. 2, at 5:05 PM PT and Wednesday, Dec. 3, at 2:40 PM PT, new analyses will be presented on benefits of continued therapy and estimated time savings over 10 year of lecanemab treatment based on Phase 3 clinical data (LB12, LB21). Subcutaneous initiation dosing: On Wednesday, Dec. 3, the late-breaking symposium, "Lecanemab Subcutaneous Formulation for Treatment Initiation in Early Alzheimer's Disease: Optimizing Patient Care with a Potential New Option" (3:10 - 3:50 PM PT), will explore potential benefits of subcutaneous lecanemab initiation dosing as well as pharmacokinetic and safety findings (LB Symposium 2). Real-world experience: A presentation on Thursday, Dec. 4, at 11:40 AM PT will share findings from an interim analysis of a post-marketing observational study of lecanemab in Japan (OC30). Mechanism-related: A presentation scheduled for Tuesday, Dec. 2, in Dec. 2, at 1:40 PM PT, will review the effects of le canemab treatment on soluble Ab protofibrils in the Clarity AD clinical trial (OC5). Key lecanemab poster presentation: Real-world experience: During the poster session on Dec. 1, at 3:00 PM PT and Tuesday, Dec. 2, At 5:30 PM PT, Poster 055 presents an overview of baseline characteristics and preliminary safety findings from a study of lecanemab In Alzheimer's disease (AD) using the ALZ-NET registry. Additional lecanemab poster presentations: Dec. 1 (Mon.) - Dec. 2 (Tues.) Real-world experience: A presented on Dec. 1 (Mon.)-Tues.) Characterizing Enrollment patterns in a Preclinical Alzheimer's Disease Trial (P006); Dec. 1 (Mon.) -- Dec. 2 (Tues) Stability and Improvement in Early Alzheimer's Disease with Lecanemab: Sub-analysis from a United States Multicenter, Retrospective Real-World Study (P049); Dec. 1 (Mon.). - Dec. 2 (Tue.) Long-Term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved (P052); Dec. 1 (Mon.), Dec. 2 (Tues.). Patient, Care Partner, and Health Care Professional Acceptability of the Autoinjector for the Subcutaneous Delivery of Lecanemab In the US (P053). Dec. 1 (Mon.).분석 기사 • Nov 16BioArctic AB (publ) (STO:BIOA B) Just Released Its Third-Quarter Earnings: Here's What Analysts ThinkIt's been a pretty great week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with its shares surging 12% to kr295...Reported Earnings • Nov 14Third quarter 2025 earnings released: kr0.98 loss per share (vs kr0.22 loss in 3Q 2024)Third quarter 2025 results: kr0.98 loss per share (further deteriorated from kr0.22 loss in 3Q 2024). Revenue: kr133.3m (up 74% from 3Q 2024). Net loss: kr86.9m (loss widened 343% from 3Q 2024). Revenue is expected to decline by 2.9% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Sweden are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.공시 • Oct 20BioArctic AB (publ), Annual General Meeting, May 28, 2026BioArctic AB (publ), Annual General Meeting, May 28, 2026, at 16:30 W. Europe Standard Time. Location: stockholm Sweden공시 • Oct 14BioArctic AB (publ) Announces First Patient Treated with Leqembi (Lecanemab) in the NordicsBioArctic AB (publ) announced that Leqembi has now been made available at a private clinic in Finland and that the first patient has started treatment. BioArctic copromotes Leqembi with its partner Eisai in the Nordic countries, and this marks an important strategic step for BioArctic on the company's journey towards building Sweden's next major pharmaceutical company. Leqembi received the European Commission (EC) approval in April 2025 as the first therapy that targets an underlying cause of Alzheimer's disease (AD). It is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD (early AD) who are apolipoprotein E e4 (ApoE e4[1]) non-carriers or heterozygotes with confirmed amyloid pathology. Following the EC approval, BioArctic and Eisai have been collaborating with the Nordic healthcare authorities to implement the mandatory authorisation requirements. The required controlled access program is now in place in Finland, enabling private clinics such as Terveystalo Ruoholahti, where the first patient was treated, to help patients with early Alzheimer´s disease. In the meantime, Leqembi is under assessment for inclusion in the publicly funded health care system. Alzheimer's disease is a progressive, relentless disease with Aß and tau as hallmarks. It progresses in stages that increase in severity over time, and each stage of the disease presents different challenges for those living with the disease and their care partners. The data show that amyloid-beta protofibrils and tau tangles play roles in the neurodegeneration process,[4],[5],[6] and Leqembi is the only approved treatment that fights Alzheimer's disease in two ways - targeting both protofibrils[i] and amyloid plaque, which can impact tau downstream. Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region.공시 • Sep 24BioArctic AB (publ) Announces the TGA Approval for the Treatment of Early Alzheimer's Disease in AustraliaBioArctic AB's (publ) announced that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi) for the treatment of adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease (early Alzheimer's disease) that are apolipoprotein E e4 (ApoE e4) non-carriers or heterozygotes, with confirmed amyloid pathology. In response to February 2025 the TGA decision not to approve lecanemab for the treatment for people with early AD, in March 2025, Eisai requested a review by the Administrative Review Tribunal. As a result of the discussions during this process, the TGA and Eisai reached an agreement that led to the approval of Leqembi. Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lann felt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region.내러티브 업데이트 • Sep 17Overhyped Valuations Will Falter Amid Healthcare HeadwindsDespite a significant improvement in BioArctic's net profit margin and a sharp decline in its future P/E multiple, the consensus analyst price target has been revised downward to SEK294.60. What's in the News FDA approved the Biologics License Application for weekly subcutaneous maintenance dosing of lecanemab (LEQEMBI IQLIK) for early Alzheimer's disease; U.S. launch set for October 6, 2025.Major Estimate Revision • Sep 08Consensus EPS estimates fall by 13%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from kr1.94b to kr2.00b. EPS estimate fell from kr13.71 to kr11.90 per share. Net income forecast to shrink 36% next year vs 19% growth forecast for Biotechs industry in Sweden . Consensus price target up from kr286 to kr293. Share price fell 6.1% to kr290 over the past week.Recent Insider Transactions • Sep 03VP and Head of IR & Communication recently sold kr1.2m worth of stockOn the 28th of August, Oskar Bosson sold around 4k shares on-market at roughly kr299 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr1.7m more than they bought in the last 12 months.Price Target Changed • Sep 02Price target increased by 8.8% to kr311Up from kr286, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of kr317. Stock is up 92% over the past year. The company is forecast to post earnings per share of kr12.81 next year compared to a net loss per share of kr2.00 last year.내러티브 업데이트 • Sep 02Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration CareBioArctic's consensus price target has been reduced to SEK280.50, primarily due to sharply lower revenue growth expectations and a significant drop in the projected future P/E multiple. What's in the News BioArctic entered an option, collaboration, and license agreement with Novartis Pharma involving its proprietary BrainTransporter technology for a potential neurodegeneration treatment, receiving USD 30 million upfront, with up to USD 772 million in potential milestone payments and tiered royalties.Reported Earnings • Aug 31Second quarter 2025 earnings released: EPS: kr1.09 (vs kr0.78 loss in 2Q 2024)Second quarter 2025 results: EPS: kr1.09 (up from kr0.78 loss in 2Q 2024). Revenue: kr392.1m (up kr342.3m from 2Q 2024). Net income: kr96.6m (up kr165.0m from 2Q 2024). Profit margin: 25% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.공시 • Aug 28+ 1 more updateBioArctic AB (publ) to Report Q1, 2026 Results on May 20, 2026BioArctic AB (publ) announced that they will report Q1, 2026 results at 8:00 AM, Central European Standard Time on May 20, 2026Valuation Update With 7 Day Price Move • Aug 27Investor sentiment improves as stock rises 18%After last week's 18% share price gain to kr276, the stock trades at a forward P/E ratio of 26x. Average trailing P/E is 31x in the Biotechs industry in Sweden. Total returns to shareholders of 190% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr496 per share.분석 기사 • Aug 14Revenues Not Telling The Story For BioArctic AB (publ) (STO:BIOA B) After Shares Rise 26%OM:BIOA B 1 Year Share Price vs Fair Value Explore BioArctic's Fair Values from the Community and select yours Despite...Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr220, the stock trades at a forward P/E ratio of 22x. Average trailing P/E is 28x in the Biotechs industry in Sweden. Total returns to shareholders of 95% over the past three years.공시 • Jun 13BioArctic to Initiate Next Cohorts in Exidavnemab Phase 2a Study After Positive Safety ReviewBioArctic AB (publ) announced that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST study evaluates exidavnemab, a drug candidate being developed as a treatment for Parkinson's disease and Multiple System Atrophy (MSA). The first cohort in the ongoing clinical Phase 2a study EXist evaluated a lower dose of exidavnemab compared to placebo in patients with Parkinson's disease. An interim safety review showed that exidavnemab was safe and well tolerated. The positive outcome will result in the initiation of two further cohorts, to evaluate a higher dose of exidavnemib in comparison with placebo in patients with Parkinson's Disease as well as MSA. The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blinded, placebo-controlled study to evaluate the safety and tolerability of exidavnemab and its pharmacokinetic profile. In addition, a broad range of biomarkers will be evaluated in plasma, cerebrospinal fluid (CSF), and using digital measurements. Exidavnemab is being developed as a novel disease-modifying treatment for synucleinopathies such as Parkinson's disease and MSA. Exidavnemab are a monoclonal antibody (mAb) that selectively targets pathological alpha-synuclein aggregates, while sparing the physiological forms. Aggregated alpha-synuclein damages nerve cells, and by selectively binding and removing these aggregates, exidavnemab is intended to preserve nerve cell function and slow the disease. There is a large unmet medical need for slowing disease progression in diseases such as Parkinson's disease andMSA. Exidavnemib has recently been granted orphan drug designation (ODD) in the US and a positive opinion regarding orphan medicinal product designation (OD) in the EU for the treatment of MSA. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.Price Target Changed • Jun 04Price target decreased by 8.0% to kr289Down from kr314, the current price target is an average from 5 analysts. New target price is 45% above last closing price of kr200. Stock is down 17% over the past year. The company is forecast to post earnings per share of kr11.92 next year compared to a net loss per share of kr2.00 last year.새로운 내러티브 • Jun 01Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care Regulatory approvals and upcoming diagnostics are set to accelerate Leqembi adoption, expanding access and recurring royalty revenues from an underserved and growing patient base.분석 기사 • May 29BioArctic's (STO:BIOA B) Solid Profits Have Weak FundamentalsBioArctic AB (publ)'s ( STO:BIOA B ) robust earnings report didn't manage to move the market for its stock. Our...New Risk • May 21New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.분석 기사 • May 16Here's Why BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation Is The Least Of Shareholders ConcernsKey Insights BioArctic will host its Annual General Meeting on 22nd of May CEO Gunilla Osswald's total compensation...Price Target Changed • May 07Price target decreased by 9.6% to kr302Down from kr335, the current price target is an average from 5 analysts. New target price is 66% above last closing price of kr182. Stock is down 6.7% over the past year. The company is forecast to post earnings per share of kr10.78 next year compared to a net loss per share of kr2.00 last year.Reported Earnings • Apr 25Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: kr2.00 loss per share (down from kr2.60 profit in FY 2023). Revenue: kr257.4m (down 58% from FY 2023). Net loss: kr177.1m (down 177% from profit in FY 2023). Products in clinical trials Phase II: 1 Phase III: 1 Post-clinical trial products Approved (during full year): 2 Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings.공시 • Apr 08BioArctic AB (publ) Presents Data on Exidavnemab and Lecanemab at 2025 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog DisordersBioArctic AB (publ) presented data on exidavnemab and lecanemab at the 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™?), held in Vienna, Austria, April 1-5. BioArctic's partner Eisai also presented new data including results from real-world use of lecanemab. At AD/PD, Dr Johanna Falting, Head of R&D at BioArctic, held an oral presentation on exidavnemab, the company's proprietary drug candidate aimed at treating Parkinson's disease and other alpha-synucleinopathies. In the Phase 1 studies, exidavnemab was generally well tolerated and demonstrated an elimination half-life of approximately 30 days. These properties make exidavnemab a suitable candidate for future studies of disease modification in alpha-synucleinopathyies. The design of the ongoing EXIST Phase 2a study in Parkinson's disease was presented. New data on lecanemab were also presented at the conference. Lecanemab is an anti-amyloid beta (Ab) monoclonal antibody that preferentially binds to toxic protofibrils (soluble Ab aggregates), in addition to targeting and reducing Ab plaques (insoluble Ab aggregates). In an oral presentation by Dr Michael Rosenbloom, University of Washington, USA, recent findings from real-world clinical evidence of lecanemab in the United States were presented. The utilization patterns showed that real-world use of le canemab conforms with the FDA approved prescribing recommendations, and patient adherence suggests that neither MRI monitoring nor possible adverse events significantly interfered with lecanemab dosing. In two other presentations, Dr Lutz Froelich, University of Heidelberg, Germany, presented the efficacy and safety outcomes of lecanemab in early AD apolipoprotein E e4 (ApoEe4) heterozygous carriers and non-carriers in the Phase 3 Clarity AD clinical study. The data presented were forming the basis for the regulatory approval in United Kingdom and the positive CHMP recommendation for EU approval, respectively. The data for the UK and EMA proposed indicated population confirmed that the effects of lecanemab were similar to the overall Clarity AD population with lower risk of ARIA events. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.공시 • Feb 21Bioarctic's Global License Agreement with Bristol Myers Squibb for Pyroglutamate-Amyloid-Beta Antibody Program Effective After Antitrust Clearance and ClosingBioArctic AB (publ) announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-Aß) antibody program to Bristol Myers Squibb. Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million. On December 19, 2024, BioArctic announced that BioArctic had entered into a global license agreement with Bristol Myers Squibb under which Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of BAN1503 and BAN2803 and related products worldwide. The agreement was subject to filing and clearance under U.S. Antitrust legislation (the Hart-Scott-Rodino Antitrust Improvements Act of 1976), a condition which has been fulfilled, and the transaction has now closed. The finalization of the agreement triggers an upfront payment of USD 100 million to BioArctic. The license agreement further includes up to USD 1.25 billion in development, regulatory and commercial milestones, as well as tiered low double-digit royalties on global product sales. BioArctic will retain an option to co-commercialize the products in the Nordic region. BioArctic's PyroGlu-Aß antibody program consists of novel antibodies targeting a specific truncated, pyroglutamate modified form of amyloid-beta. Monomers of PyroGlu-Aß are highly prone to aggregate, leading to the formation of harmful aggregates which cause debilitating cognitive and other symptoms in Alzheimer's disease. The agreement includes both the BAN1503 and BAN2803 antibodies. BAN2803 includes BioArctic'sBrainTransporter™ technology.Recent Insider Transactions Derivative • Feb 19Insider exercised options to buy kr5.9m worth of stock.On the 13th of February, Johanna Fälting exercised 40.00k options at around kr83.60, then sold 15.00k of them at kr221 each and kept the remainder. Since June 2024, Johanna has owned 44.86k shares directly. Company insiders have collectively sold kr265k more than they bought, via options and on-market transactions in the last 12 months.분석 기사 • Feb 19Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...분석 기사 • Feb 18Earnings Beat: BioArctic AB (publ) (STO:BIOA B) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsIt's been a good week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, because the company has just released its...Reported Earnings • Feb 14Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: kr2.00 loss per share (down from kr2.60 profit in FY 2023). Revenue: kr257.4m (down 58% from FY 2023). Net loss: kr177.1m (down 177% from profit in FY 2023). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.분석 기사 • Jan 31Analysts Just Published A Bright New Outlook For BioArctic AB (publ)'s (STO:BIOA B)Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...Recent Insider Transactions • Dec 26VP and Head of IR & Communication recently sold kr776k worth of stockOn the 19th of December, Oskar Bosson sold around 3k shares on-market at roughly kr224 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr1.1m more than they bought in the last 12 months.New Risk • Dec 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.공시 • Dec 05BioArctic AB (publ) Announces Dosing of First Patient in EXIST Phase 2a Study in Parkinson's DiseaseBioArctic AB (publ) announced that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein a-synuclein, believed to play a role in the disease progression in different neurological disorders including Parkinson's disease. The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blind, placebo-controlled study in Parkinson's disease patients to evaluate the safety and tolerability of exidavnemab. The study is conducted in Europe and at least 24 patients will be recruited in, divided into two cohorts of 12 (Cohort 1 and Cohort 2). Participants in Cohort 1 will receive either a lower dose of exidavnemab or placebo and participants in Cohort 2 will receive either a higher dose of exidavnEMab or placebo. In addition to the primary endpoints, a broad range of biomarkers will be evaluated, in plasma, cerebrospinal fluid (CSF) and using digital measurements. Recently, the results of two separate Phase 1 studies of exidavnemab, conducted in collaboration with AbbVie, were published in The Journal of Clinical Pharmacology. The results showed that exidavnemab is generally well-tolerated, with an excellent half-life of approximately 30 days. These data together with the highinity and selectivity toward the pathological aggregated forms of a-synuclein, key to maintaining a high target binding in the brain, laid the foundation for the Phase 2a study.분석 기사 • Nov 27Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)Celebrations may be in order for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with the analysts delivering a...Price Target Changed • Nov 20Price target increased by 9.8% to kr321Up from kr292, the current price target is an average from 5 analysts. New target price is 80% above last closing price of kr179. Stock is down 24% over the past year. The company is forecast to post a net loss per share of kr2.69 compared to earnings per share of kr2.60 last year.Reported Earnings • Nov 15Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: kr0.22 loss per share (down from kr1.42 profit in 3Q 2023). Revenue: kr76.6m (down 63% from 3Q 2023). Net loss: kr19.6m (down 116% from profit in 3Q 2023). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 56%. Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 14% per year.공시 • Nov 15Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EUBioArctic AB (publ) announced that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization application (MAA) for lecanemab as treatment of Alzheimer's disease. The recommendation applies to the treatment of early Alzheimer's disease in adult patients that are apolipoprotein E e4 (ApoE e4) heterozygotes or non-carriers. The CHMP recommendation for the European Commission to approve lecanemab follows Eisai's request for a re-examination of the CHMP's earlier negative recommendation. A decision from the European Commission is expected within 67 days. The CHMP recommends approval of lecanemab for the treatment of mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease, in adult patients who are heterozygotes (carry one copy) or are non-carriers of the Apolipoprotein E e4 (ApoE e4) gene. Lecanemab is already approved in the US, Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, and the Great Britain. Eisai is responsible for the clinical development, applications for market approval and commercialization of lecanemab for Alzheimer's disease. BioArctic has the rights to commercialize lecanemab in the Nordic region. Currently, BioArctic and Eisai are preparing for joint commercialization in these countries, pending approval from the European Commission.공시 • Nov 14+ 3 more updatesBioArctic AB (publ) to Report Q2, 2025 Results on Aug 28, 2025BioArctic AB (publ) announced that they will report Q2, 2025 results on Aug 28, 2025공시 • Oct 13BioArctic AB (publ) Presents Nomination CommitteePursuant to the instruction regarding the appointment of the Nomination Committee BioArctic AB’s (publ) shall have a Nomination Committee comprising one representative for each of the three principal shareholders in terms of votes, based on the information received from Euroclear Sweden AB on the last banking day in September 2024, as well as the Chairman of the Board (convener). September 30, 2024, the three largest shareholders were Demban AB, Ackelsta AB and The Fourth Swedish National Fund (Fjärde AP-fonden). The three owners who have agreed to be part of the Nomination Committee, Demban AB, Ackelsta AB and Fjärde AP-fonden, represent approx. 61% of the shares and approx. 84% of the votes in the company. The nomination committee comprises the following members: Margareta Öhrvall, appointed by Demban AB, Claes Andersson, appointed by Ackelsta AB, Jannis Kitsakis, chairperson of the Nomination Committee appointed by Fjärde AP-fonden. The Nomination Committee shall prepare proposals for the 2025 Annual General Meeting regarding the Chairman of the Meeting, number of Board members, fees to be paid to the Chairman of the Board and Board members, election of Board members and Board Chairman, remuneration to the auditor and election of auditor and, if necessary, proposal for changes in the instruction to the Nomination Committee.공시 • Oct 12BioArctic AB (publ), Annual General Meeting, May 22, 2025BioArctic AB (publ), Annual General Meeting, May 22, 2025, at 16:30 W. Europe Standard Time. Location: stockholm SwedenRecent Insider Transactions Derivative • Sep 16Vice President of Human Resources exercised options and sold kr454k worth of stockOn the 12th of September, Gunilla Andersson exercised 5k options at a strike price of around kr83.10 and sold these shares for an average price of kr174 per share. This trade did not impact their existing holding. As of today, Gunilla currently holds no shares directly. Company insiders have collectively sold kr68k more than they bought, via options and on-market transactions in the last 12 months.분석 기사 • Sep 01BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportA week ago, BioArctic AB (publ) ( STO:BIOA B ) came out with a strong set of quarterly numbers that could potentially...Price Target Changed • Aug 30Price target decreased by 9.3% to kr291Down from kr320, the current price target is an average from 5 analysts. New target price is 75% above last closing price of kr167. Stock is down 47% over the past year. The company is forecast to post a net loss per share of kr1.13 compared to earnings per share of kr2.60 last year.Reported Earnings • Aug 30Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: kr0.77 loss per share (improved from kr1.16 loss in 2Q 2023). Revenue: kr50.4m (up kr47.7m from 2Q 2023). Net loss: kr68.4m (loss narrowed 33% from 2Q 2023). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.공시 • Aug 27BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical PharmacologyBioArctic AB (publ) announced that the results from two phase-1 studies with exidavnemab have been published in The Journal of Clinical Pharmacology. Exidavnemab is a drug candidate under development aimed at treating diseases such as Parkinson's disease. It is a monoclonal antibody designed to target aggregated forms of the protein -synuclein, while sparing the physiological form of the protein. In two separate phase 1 clinical studies conducted in collaboration with AbbVie, exidavnemab was tested on healthy volunteers to assess the safety, tolerability and pharmacokinetics of the candidate drug. The studies included 98 participants from different ethnic backgrounds, of which 85 received exidavnemab, either as an intravenous dose ranging from 100 to 6000 mg or a subcutaneous dose of 300 mg. The results showed that exidavnemab was generally well-tolerated. with an excellent half-life of approximately 30 days. This together with the high affinity and selectivity toward the pathological aggregated forms of -synuclein is key to maintain a high target binding in the brain.분석 기사 • Aug 15Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024The analysts covering BioArctic AB (publ) ( STO:BIOA B ) delivered a dose of negativity to shareholders today, by...Price Target Changed • Jul 30Price target decreased by 8.6% to kr336Down from kr368, the current price target is an average from 5 analysts. New target price is 114% above last closing price of kr157. Stock is down 47% over the past year. The company is forecast to post a net loss per share of kr0.22 compared to earnings per share of kr2.60 last year.New Risk • Jul 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Lotta Ljungqvist was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Recent Insider Transactions • May 27Insider recently sold kr710k worth of stockOn the 24th of May, Johanna Fälting sold around 3k shares on-market at roughly kr237 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr3.4m more than they bought in the last 12 months.공시 • May 25BioArctic AB (publ) Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South KoreaBioArctic AB (publ) announced that the Ministry of Food and Drug Safety (MFDS) in South Korea published that Leqembi® (lecanemab) has been approved for treatment in patients with mild cognitive impairment due to Alzheimer's disease (AD) and mild AD (early AD).Reported Earnings • May 19First quarter 2024 earnings: Revenues exceed analyst expectationsFirst quarter 2024 results: Revenue: kr29.6m (down 93% from 1Q 2023). Net loss: kr57.6m (down 120% from profit in 1Q 2023). Revenue exceeded analyst estimates by 63%. Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 21Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: EPS: kr2.60 (up from kr0.13 loss in FY 2022). Revenue: kr616.0m (up 169% from FY 2022). Net income: kr229.2m (up kr240.4m from FY 2022). Profit margin: 37% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Products in clinical trials Phase I: 2 Phase III: 1 Post-clinical trial products Pre-registration: 1 Approved (during full year): 1 Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 24%. Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.분석 기사 • Apr 13Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)With a price-to-sales (or "P/S") ratio of 30.5x BioArctic AB (publ) ( STO:BIOA B ) may be sending very bearish signals...공시 • Mar 14BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersBioArctic AB (publ) and its partner Eisai presented new data on lecanemab (brand name: Leqembi) at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD), held in Lisbon, Portugal and virtually, March 5-9. BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aß) antibody lecanemab and other anti Aß antibodies. Lecanemab was designed to preferentially bind soluble (protofibrils), as well as insoluble Aß aggregates (fibrils), to reduce both Aß protofibrils and Aß plaques in the brain. The difference in binding to CAA was presented, with lecanemab having lower binding to CAA than most other antibodies. This could explain the difference in the adverse event ARIA seen between different antibodies, with lecanemab showing relatively low incidence of ARIA. In another presentation Professor Christopher van Dyke presented extended efficacy results from the Phase 3 Clarity AD open label extension study of lecanemab in Alzheimer's disease up to 30 months, showing continued benefit with lecanemab treatment. Professor van Dyke also highlighted data from the tau sub-study of Clarity AD, which showed that all cohorts of the tau population benefitted from treatment with lecanemab. Data from the low tau population, representing earlier stages of the disease, indicated that intervening in early stages of disease may be particularly impactful in stabilizing the disease process. Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and the anti Aß protofibril antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for commercialization in the region.Major Estimate Revision • Mar 10Consensus EPS estimates increase by 112%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from kr494.3m to kr502.5m. EPS estimate increased from kr0.094 to kr0.199 per share. Net income forecast to shrink 93% next year vs 14% growth forecast for Biotechs industry in Sweden . Consensus price target broadly unchanged at kr366. Share price rose 6.4% to kr233 over the past week.Recent Insider Transactions Derivative • Feb 21Vice President of Human Resources exercised options to buy kr1.2m worth of stock.On the 18th of February, Gunilla Andersson exercised options to buy 5k shares at a strike price of around kr83.60, costing a total of kr418k. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. As of today, Gunilla currently holds no shares directly. Company insiders have collectively sold kr1.9m more than they bought, via options and on-market transactions in the last 12 months.분석 기사 • Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under ThreatThe latest analyst coverage could presage a bad day for BioArctic AB (publ) ( STO:BIOA B ), with the analysts making...Reported Earnings • Feb 18Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: EPS: kr2.60 (up from kr0.13 loss in FY 2022). Revenue: kr620.1m (up 170% from FY 2022). Net income: kr229.2m (up kr240.4m from FY 2022). Profit margin: 37% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Products in clinical trials Phase I: 1 Phase III: 1 Post-clinical trial products Approved (during full year): 1 Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 24%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.Major Estimate Revision • Feb 16Consensus revenue estimates fall by 15%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr595.9m to kr509.3m. EPS estimate fell from kr1.83 to kr0.352 per share. Net income forecast to shrink 73% next year vs 16% growth forecast for Biotechs industry in Sweden . Consensus price target broadly unchanged at kr374. Share price rose 8.3% to kr228 over the past week.분석 기사 • Feb 03News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under ThreatThe analysts covering BioArctic AB (publ) ( STO:BIOA B ) delivered a dose of negativity to shareholders today, by...공시 • Jan 11+ 1 more updateThe European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemabBioArctic AB's (publ) announced that the Scientific Advisory Group (SAG) will convene to discuss the Marketing Authorisation Application (MAA) of lecanemab (generic name, brand name: Leqembi®), which is currently under review by the European Medicines Agency (EMA). The meeting of the SAG is expected to take place during the first quarter of 2024. The SAG is convened at the request of the Committee for Medicinal Products for Human Use (CHMP) of the EMA to provide independent advice on scientific or technical matters relating to products under evaluation by the CHMP, or on other scientific issues relevant to the work of the CHMP. It is a commonly used procedure for new treatments and new treatment concepts. Eisai expects the European Commission's decision for the MAA of lecanemab in the second quarter of 2024, if the opinion from the CHMP is received by March 31, 2024, following discussion by the SAG. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region.분석 기사 • Dec 23Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) RevenuesBioArctic AB (publ)'s ( STO:BIOA B ) price-to-sales (or "P/S") ratio of 39.1x might make it look like a strong sell...Major Estimate Revision • Nov 21Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr627.2m to kr527.9m. EPS estimate fell from kr2.85 to kr1.89 per share. Net income forecast to shrink 14% next year vs 12% growth forecast for Biotechs industry in Sweden . Consensus price target broadly unchanged at kr372. Share price rose 3.3% to kr234 over the past week.Major Estimate Revision • Nov 15Consensus revenue estimates fall by 14%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr729.8m to kr627.1m. EPS estimate fell from kr3.45 to kr2.84 per share. Net income forecast to shrink 1.5% next year vs 30% growth forecast for Biotechs industry in Sweden . Consensus price target down from kr392 to kr372. Share price rose 4.5% to kr223 over the past week.이익 및 매출 성장 예측OM:BIOA B - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20282,432993981991412/31/20271,769842893856412/31/20261,27532633334343/31/20261,1472131,2431,253N/A12/31/20251,9991,0221,4211,431N/A9/30/20251,9161,0001,0641,090N/A6/30/20251,8601,0671,0251,051N/A3/31/20251,517902-217-190N/A12/31/2024257-177-343-316N/A9/30/2024167-233-171-163N/A6/30/2024299-88-142-134N/A3/31/2024252-122-111-104N/A12/31/2023616229302310N/A9/30/2023607259113126N/A6/30/2023617270284289N/A3/31/2023619327294307N/A12/31/2022229-11-44-32N/A9/30/202223228-15-13N/A6/30/202218-147-170-159N/A3/31/202221-135-147-143N/A12/31/202126-120-145-140N/A9/30/202130-114-138-128N/A6/30/202137-97-114-103N/A3/31/202134-101-106-93N/A12/31/202065-69-105-92N/A9/30/202084-72-125-120N/A6/30/202093-60-163-160N/A3/31/202025278-46-43N/A12/31/201928388N/A327N/A9/30/2019779441N/A292N/A6/30/2019852475N/A310N/A3/31/2019729380N/A176N/A12/31/2018722382N/A-200N/A9/30/201825758N/A-157N/A6/30/201819732N/A-149N/A3/31/201819429N/A-139N/A12/31/201715715N/A-135N/A9/30/201719378N/A616N/A6/30/201716071N/A630N/A3/31/201712764N/A647N/A12/31/201610658N/A675N/A12/31/2015424N/A-16N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: BIOA B 의 연간 예상 수익 증가율(53.3%)이 saving rate(2%)보다 높습니다.수익 vs 시장: BIOA B 의 연간 수익(53.3%)이 Swedish 시장(8.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: BIOA B 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: BIOA B 의 수익(연간 28.7%)이 Swedish 시장(연간 0.04%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: BIOA B 의 수익(연간 28.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: BIOA B의 자본 수익률은 3년 후 35.8%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 13:53종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioArctic AB (publ)는 5명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kristofer Liljeberg-SvenssonDNB CarnegieRajan SharmaGoldman SachsViktor SundbergNordea Markets2명의 분석가 더 보기
분석 기사 • 6hBioArctic AB (publ) Just Reported A Surprise Profit, And Analysts Lifted Their EstimatesAs you might know, BioArctic AB (publ) ( STO:BIOA B ) recently reported its quarterly numbers. Revenues of 66% beat...
Major Estimate Revision • May 18Consensus EPS estimates increase by 344%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from kr1.20b to kr1.25b. EPS estimate increased from kr0.66 to kr2.93 per share. Net income forecast to shrink 75% next year vs 9.0% growth forecast for Biotechs industry in Sweden . Consensus price target of kr301 unchanged from last update. Share price was steady at kr324 over the past week.
Major Estimate Revision • Feb 25Consensus EPS estimates fall by 72%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from kr1.13b to kr1.23b. EPS estimate fell from kr2.32 to kr0.66 per share. Net income forecast to shrink 72% next year vs 11% growth forecast for Biotechs industry in Sweden . Consensus price target broadly unchanged at kr304. Share price fell 13% to kr318 over the past week.
분석 기사 • Nov 16BioArctic AB (publ) (STO:BIOA B) Just Released Its Third-Quarter Earnings: Here's What Analysts ThinkIt's been a pretty great week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with its shares surging 12% to kr295...
Major Estimate Revision • Sep 08Consensus EPS estimates fall by 13%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from kr1.94b to kr2.00b. EPS estimate fell from kr13.71 to kr11.90 per share. Net income forecast to shrink 36% next year vs 19% growth forecast for Biotechs industry in Sweden . Consensus price target up from kr286 to kr293. Share price fell 6.1% to kr290 over the past week.
Price Target Changed • Sep 02Price target increased by 8.8% to kr311Up from kr286, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of kr317. Stock is up 92% over the past year. The company is forecast to post earnings per share of kr12.81 next year compared to a net loss per share of kr2.00 last year.
분석 기사 • 6hBioArctic AB (publ) Just Reported A Surprise Profit, And Analysts Lifted Their EstimatesAs you might know, BioArctic AB (publ) ( STO:BIOA B ) recently reported its quarterly numbers. Revenues of 66% beat...
Upcoming Dividend • May 22Upcoming dividend of kr2.00 per shareEligible shareholders must have bought the stock before 29 May 2026. Payment date: 04 June 2026. Payout ratio is on the higher end at 83%, however this is supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Swedish dividend payers (4.1%). Lower than average of industry peers (2.2%).
New Risk • May 21New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 19% Last year net profit margin: 59% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
속보 • May 20FDA Pushes Leqembi Iqlik Decision to August 2026 Keeping BioArctic in Global SpotlightThe FDA has extended its review of the supplemental Biologics License Application for Leqembi Iqlik, a once-weekly subcutaneous formulation for early Alzheimer's disease, pushing the PDUFA date to 24 August 2026 after requesting additional information classified as a major amendment. Regulators have not raised concerns about the approvability of Leqembi Iqlik, while Leqembi is already authorized in more than 50 countries and Eisai and BioArctic are preparing for joint commercialization of the subcutaneous product in the Nordic region. Eisai’s Leqembi sales in its 2025 fiscal year surpassed €500m, triggering a €20m milestone payment to BioArctic. Long-term and real-world data suggest patients stay on treatment for extended periods, with disease-slowing effects observed for up to four years, even as Sweden’s NT Council has denied reimbursement and other submissions progress in the EU, US and China. The FDA review extension introduces a longer timeline for the new formulation, but the breadth of existing approvals and ongoing global submissions keep Leqembi central to BioArctic’s commercial story. Investors may want to pay close attention to future regulatory and reimbursement decisions, since they directly affect the pace and scale of potential royalty streams and milestone payments to BioArctic.
Major Estimate Revision • May 18Consensus EPS estimates increase by 344%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from kr1.20b to kr1.25b. EPS estimate increased from kr0.66 to kr2.93 per share. Net income forecast to shrink 75% next year vs 9.0% growth forecast for Biotechs industry in Sweden . Consensus price target of kr301 unchanged from last update. Share price was steady at kr324 over the past week.
내러티브 업데이트 • May 18BIOA B: Future Returns Will Depend On High NLRP3 Execution RiskAnalysts kept their SEK 240.00 price target for BioArctic unchanged, with slightly lower discount rate and profit margin assumptions, and a higher future P/E multiple that reflects refined views on the stock's risk profile and earnings power. Analyst Commentary Recent research on BioArctic has centered on how changing assumptions around risk, profitability, and long term earnings power feed into valuation.
Reported Earnings • Apr 26Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: kr11.55 (up from kr2.00 loss in FY 2024). Revenue: kr2.00b (up kr1.74b from FY 2024). Net income: kr1.02b (up kr1.20b from FY 2024). Profit margin: 51% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
내러티브 업데이트 • Apr 22BIOA B: Future Returns Will Depend On High NLRP3 Execution RiskAnalysts have kept their SEK 240.0 price target for BioArctic unchanged, explaining the steady view by slightly adjusting discount rate, revenue growth, profit margin and future P/E assumptions, while balancing higher perceived risk with ongoing optimism around the broader NLRP3 and cardiovascular opportunity highlighted in recent peer research. Analyst Commentary Research coverage around NLRP3-targeted therapies has been active, with several firms updating their views and price targets on peers such as BioAge Labs.
내러티브 업데이트 • Apr 08BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced OutlookThe analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.
공시 • Mar 28Bioarctic AB Announces Declining of Re-Election by Pär Gellerfors as Board MemberBioArctic AB at the Annual General Meeting to be held on May 28, 2026 announced that Board member Pär Gellerfors has declined re-election.
내러티브 업데이트 • Mar 25BIOA B: Future Earnings Will Depend On High China Access RiskAnalysts have nudged their fair value estimate for BioArctic to SEK240 from SEK236. This reflects updated assumptions around revenue contraction, profitability and a higher future P/E multiple, while keeping the discount rate broadly similar.
내러티브 업데이트 • Mar 10BIOA B: China Alzheimer’s Access And Delivery Shift Will Drive Future UpsideAnalysts are keeping their SEK 367.0 price target for BioArctic broadly unchanged, with only modest tweaks to underlying assumptions. They highlight parallels with recent bullish Street research on early stage biotech names that are seeing renewed interest around differentiated clinical assets.
Major Estimate Revision • Feb 25Consensus EPS estimates fall by 72%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from kr1.13b to kr1.23b. EPS estimate fell from kr2.32 to kr0.66 per share. Net income forecast to shrink 72% next year vs 11% growth forecast for Biotechs industry in Sweden . Consensus price target broadly unchanged at kr304. Share price fell 13% to kr318 over the past week.
내러티브 업데이트 • Feb 24BIOA B: Peer Re-Rating And China Alzheimer’s Momentum Will Reframe UpsideAnalysts have raised their BioArctic fair value estimate from SEK353 to SEK367 as they factor in updated views on revenue growth, margins, discount rate and a higher future P/E assumption aligned with recent bullish Street research on comparable biotech names. Analyst Commentary Recent Street research on comparable biotech names has turned more optimistic, with bullish analysts revisiting their models and price targets in light of updated clinical views and perceived market potential.
Reported Earnings • Feb 19Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: kr11.55 (up from kr2.00 loss in FY 2024). Revenue: kr2.00b (up kr1.74b from FY 2024). Net income: kr1.02b (up kr1.20b from FY 2024). Profit margin: 51% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
공시 • Feb 18+ 1 more updateBioArctic AB (publ) to Report Q3, 2026 Results on Nov 25, 2026BioArctic AB (publ) announced that they will report Q3, 2026 results on Nov 25, 2026
공시 • Feb 11BioArctic AB (publ) to Report Q4, 2025 Results on Feb 18, 2026BioArctic AB (publ) announced that they will report Q4, 2025 results at 8:00 AM, Central European Standard Time on Feb 18, 2026
공시 • Feb 10Bioarctic AB (Publ) for Subcutaneous Formulation of Leqembi Designated for Priority Review in ChinaBioArctic AB's (publ) partner Eisai announced that the Biologics License Application (BLA) for the treatment of early Alzheimer's disease with Leqembi (lecanemab), using a subcutaneous autoinjector (SC-AI), has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. The BLA for the subcutaneous formulation was accepted for review by the NMPA in January 2026. The Priority Review and Approval Procedure has been implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened. If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration every two weeks in a hospital setting. The potential approval of SC-AI would expand the option for patients and care partners to receive Leqembi treatment at home. Eisai estimates that in 2024 there were 17 million patients with Mild Cognitive Impairment (MCI) or mild disease due to Alzheimer's disease in China, a number that is expected to rise as the population ages. Leqembi was launched in China in June 2024 and is available to the private market. Furthermore, Leqembi has been included in the newly introduced "Commercial Insurance Innovative Drug List" which took effect in January 2026, under new Chinese government policies that support the development of and access to innovative medicines. Based on the Commercial Insurance Innovative Drug List, commercial insurance companies will develop insurance products covering Leqembi. Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lann felt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug list", recently introduced by the National Healthcare Security Administration (NHSA) of China. In January 2026, Eisai's supplemental Biologics License Application regarding a subcutaneous starting dose with Leqembi Iqlik was granted Priority Review by the US FDA with a May 24, 2026, PDUFA date. Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2026, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington, Sweden.
내러티브 업데이트 • Feb 09BIOA B: Future Earnings Will Depend On Risky China Insurance AccessAnalysts have raised their fair value estimate for BioArctic from SEK 230 to SEK 236, citing updated assumptions regarding discount rates, revenue growth, profit margins and a slightly higher future P/E multiple. Analyst Commentary Recent analyst work on comparable neurology and biotech names highlights how sensitive valuations can be to small shifts in assumptions around discount rates, revenue build, profitability and terminal P/E multiples.
내러티브 업데이트 • Jan 25BIOA B: Future Earnings Will Rely On Risky China Alzheimer AccessAnalysts now keep their price target for BioArctic at SEK 230.00, with small adjustments to the discount rate, revenue growth assumptions and future P/E outlook. This reflects only minor changes to their overall view of the company’s risk and profitability profile.
New Risk • Jan 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 68% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risk Significant insider selling over the past 3 months (kr54m sold).
내러티브 업데이트 • Jan 09BIOA B: Future Earnings Will Depend On Risky Alzheimer Access RolloutAnalysts have maintained their fair value estimate for BioArctic at SEK 230.00. They have, however, adjusted assumptions related to the discount rate, revenue trends, profit margins, and future P/E to reflect updated views on the company’s risk profile and earnings potential.
내러티브 업데이트 • Dec 26BIOA B Future Long Term Margin Upside Will Not Offset Demand RisksAnalysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.
Recent Insider Transactions • Dec 22Co-Founder recently sold kr54m worth of stockOn the 18th of December, Lars Lannfelt sold around 174k shares on-market at roughly kr310 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Lars' only on-market trade for the last 12 months.
내러티브 업데이트 • Dec 12BIOA B: Future Revenue Weakness Will Outweigh Expanding Alzheimer’s Market ApprovalAnalysts have reduced their price target on BioArctic from SEK 280 to SEK 230. This reflects a more cautious outlook on future revenue growth despite improved profitability expectations and a slightly higher discount rate.
Recent Insider Transactions • Dec 07VP & Head of CMC recently sold kr320k worth of stockOn the 4th of December, Mikael Moge sold around 1k shares on-market at roughly kr320 per share. This transaction amounted to 8.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr2.2m more than they bought in the last 12 months.
공시 • Nov 19BioArctic AB's (publ) Partner Eisai to Present the Latest Findings on Lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease ConferenceBioArctic AB's (publ) partner Eisai will present the latest findings on lecanemab (Leqembi®?) at the Clinical Trials on Alzheimer's Disease (CTAD) conference, being held in San Diego December 1-4. Presentations will include data on long-term treatment and estimated time savings over 10 years, as well as safety and potential benefits of subcutaneous administration of lecanemab for initiation dosing. In addition, data on the effects of lecanemab on soluble amyloid-beta (Ab) protofibrils and insights from real-world clinical practice studies, including the US ALZ-NET registry, will also be presented. Key oral presentations: Continued treatment: On Tuesday, Dec. 2, at 5:05 PM PT and Wednesday, Dec. 3, at 2:40 PM PT, new analyses will be presented on benefits of continued therapy and estimated time savings over 10 year of lecanemab treatment based on Phase 3 clinical data (LB12, LB21). Subcutaneous initiation dosing: On Wednesday, Dec. 3, the late-breaking symposium, "Lecanemab Subcutaneous Formulation for Treatment Initiation in Early Alzheimer's Disease: Optimizing Patient Care with a Potential New Option" (3:10 - 3:50 PM PT), will explore potential benefits of subcutaneous lecanemab initiation dosing as well as pharmacokinetic and safety findings (LB Symposium 2). Real-world experience: A presentation on Thursday, Dec. 4, at 11:40 AM PT will share findings from an interim analysis of a post-marketing observational study of lecanemab in Japan (OC30). Mechanism-related: A presentation scheduled for Tuesday, Dec. 2, in Dec. 2, at 1:40 PM PT, will review the effects of le canemab treatment on soluble Ab protofibrils in the Clarity AD clinical trial (OC5). Key lecanemab poster presentation: Real-world experience: During the poster session on Dec. 1, at 3:00 PM PT and Tuesday, Dec. 2, At 5:30 PM PT, Poster 055 presents an overview of baseline characteristics and preliminary safety findings from a study of lecanemab In Alzheimer's disease (AD) using the ALZ-NET registry. Additional lecanemab poster presentations: Dec. 1 (Mon.) - Dec. 2 (Tues.) Real-world experience: A presented on Dec. 1 (Mon.)-Tues.) Characterizing Enrollment patterns in a Preclinical Alzheimer's Disease Trial (P006); Dec. 1 (Mon.) -- Dec. 2 (Tues) Stability and Improvement in Early Alzheimer's Disease with Lecanemab: Sub-analysis from a United States Multicenter, Retrospective Real-World Study (P049); Dec. 1 (Mon.). - Dec. 2 (Tue.) Long-Term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved (P052); Dec. 1 (Mon.), Dec. 2 (Tues.). Patient, Care Partner, and Health Care Professional Acceptability of the Autoinjector for the Subcutaneous Delivery of Lecanemab In the US (P053). Dec. 1 (Mon.).
분석 기사 • Nov 16BioArctic AB (publ) (STO:BIOA B) Just Released Its Third-Quarter Earnings: Here's What Analysts ThinkIt's been a pretty great week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with its shares surging 12% to kr295...
Reported Earnings • Nov 14Third quarter 2025 earnings released: kr0.98 loss per share (vs kr0.22 loss in 3Q 2024)Third quarter 2025 results: kr0.98 loss per share (further deteriorated from kr0.22 loss in 3Q 2024). Revenue: kr133.3m (up 74% from 3Q 2024). Net loss: kr86.9m (loss widened 343% from 3Q 2024). Revenue is expected to decline by 2.9% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Sweden are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
공시 • Oct 20BioArctic AB (publ), Annual General Meeting, May 28, 2026BioArctic AB (publ), Annual General Meeting, May 28, 2026, at 16:30 W. Europe Standard Time. Location: stockholm Sweden
공시 • Oct 14BioArctic AB (publ) Announces First Patient Treated with Leqembi (Lecanemab) in the NordicsBioArctic AB (publ) announced that Leqembi has now been made available at a private clinic in Finland and that the first patient has started treatment. BioArctic copromotes Leqembi with its partner Eisai in the Nordic countries, and this marks an important strategic step for BioArctic on the company's journey towards building Sweden's next major pharmaceutical company. Leqembi received the European Commission (EC) approval in April 2025 as the first therapy that targets an underlying cause of Alzheimer's disease (AD). It is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD (early AD) who are apolipoprotein E e4 (ApoE e4[1]) non-carriers or heterozygotes with confirmed amyloid pathology. Following the EC approval, BioArctic and Eisai have been collaborating with the Nordic healthcare authorities to implement the mandatory authorisation requirements. The required controlled access program is now in place in Finland, enabling private clinics such as Terveystalo Ruoholahti, where the first patient was treated, to help patients with early Alzheimer´s disease. In the meantime, Leqembi is under assessment for inclusion in the publicly funded health care system. Alzheimer's disease is a progressive, relentless disease with Aß and tau as hallmarks. It progresses in stages that increase in severity over time, and each stage of the disease presents different challenges for those living with the disease and their care partners. The data show that amyloid-beta protofibrils and tau tangles play roles in the neurodegeneration process,[4],[5],[6] and Leqembi is the only approved treatment that fights Alzheimer's disease in two ways - targeting both protofibrils[i] and amyloid plaque, which can impact tau downstream. Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region.
공시 • Sep 24BioArctic AB (publ) Announces the TGA Approval for the Treatment of Early Alzheimer's Disease in AustraliaBioArctic AB's (publ) announced that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi) for the treatment of adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease (early Alzheimer's disease) that are apolipoprotein E e4 (ApoE e4) non-carriers or heterozygotes, with confirmed amyloid pathology. In response to February 2025 the TGA decision not to approve lecanemab for the treatment for people with early AD, in March 2025, Eisai requested a review by the Administrative Review Tribunal. As a result of the discussions during this process, the TGA and Eisai reached an agreement that led to the approval of Leqembi. Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lann felt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region.
내러티브 업데이트 • Sep 17Overhyped Valuations Will Falter Amid Healthcare HeadwindsDespite a significant improvement in BioArctic's net profit margin and a sharp decline in its future P/E multiple, the consensus analyst price target has been revised downward to SEK294.60. What's in the News FDA approved the Biologics License Application for weekly subcutaneous maintenance dosing of lecanemab (LEQEMBI IQLIK) for early Alzheimer's disease; U.S. launch set for October 6, 2025.
Major Estimate Revision • Sep 08Consensus EPS estimates fall by 13%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from kr1.94b to kr2.00b. EPS estimate fell from kr13.71 to kr11.90 per share. Net income forecast to shrink 36% next year vs 19% growth forecast for Biotechs industry in Sweden . Consensus price target up from kr286 to kr293. Share price fell 6.1% to kr290 over the past week.
Recent Insider Transactions • Sep 03VP and Head of IR & Communication recently sold kr1.2m worth of stockOn the 28th of August, Oskar Bosson sold around 4k shares on-market at roughly kr299 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr1.7m more than they bought in the last 12 months.
Price Target Changed • Sep 02Price target increased by 8.8% to kr311Up from kr286, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of kr317. Stock is up 92% over the past year. The company is forecast to post earnings per share of kr12.81 next year compared to a net loss per share of kr2.00 last year.
내러티브 업데이트 • Sep 02Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration CareBioArctic's consensus price target has been reduced to SEK280.50, primarily due to sharply lower revenue growth expectations and a significant drop in the projected future P/E multiple. What's in the News BioArctic entered an option, collaboration, and license agreement with Novartis Pharma involving its proprietary BrainTransporter technology for a potential neurodegeneration treatment, receiving USD 30 million upfront, with up to USD 772 million in potential milestone payments and tiered royalties.
Reported Earnings • Aug 31Second quarter 2025 earnings released: EPS: kr1.09 (vs kr0.78 loss in 2Q 2024)Second quarter 2025 results: EPS: kr1.09 (up from kr0.78 loss in 2Q 2024). Revenue: kr392.1m (up kr342.3m from 2Q 2024). Net income: kr96.6m (up kr165.0m from 2Q 2024). Profit margin: 25% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.
공시 • Aug 28+ 1 more updateBioArctic AB (publ) to Report Q1, 2026 Results on May 20, 2026BioArctic AB (publ) announced that they will report Q1, 2026 results at 8:00 AM, Central European Standard Time on May 20, 2026
Valuation Update With 7 Day Price Move • Aug 27Investor sentiment improves as stock rises 18%After last week's 18% share price gain to kr276, the stock trades at a forward P/E ratio of 26x. Average trailing P/E is 31x in the Biotechs industry in Sweden. Total returns to shareholders of 190% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr496 per share.
분석 기사 • Aug 14Revenues Not Telling The Story For BioArctic AB (publ) (STO:BIOA B) After Shares Rise 26%OM:BIOA B 1 Year Share Price vs Fair Value Explore BioArctic's Fair Values from the Community and select yours Despite...
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr220, the stock trades at a forward P/E ratio of 22x. Average trailing P/E is 28x in the Biotechs industry in Sweden. Total returns to shareholders of 95% over the past three years.
공시 • Jun 13BioArctic to Initiate Next Cohorts in Exidavnemab Phase 2a Study After Positive Safety ReviewBioArctic AB (publ) announced that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST study evaluates exidavnemab, a drug candidate being developed as a treatment for Parkinson's disease and Multiple System Atrophy (MSA). The first cohort in the ongoing clinical Phase 2a study EXist evaluated a lower dose of exidavnemab compared to placebo in patients with Parkinson's disease. An interim safety review showed that exidavnemab was safe and well tolerated. The positive outcome will result in the initiation of two further cohorts, to evaluate a higher dose of exidavnemib in comparison with placebo in patients with Parkinson's Disease as well as MSA. The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blinded, placebo-controlled study to evaluate the safety and tolerability of exidavnemab and its pharmacokinetic profile. In addition, a broad range of biomarkers will be evaluated in plasma, cerebrospinal fluid (CSF), and using digital measurements. Exidavnemab is being developed as a novel disease-modifying treatment for synucleinopathies such as Parkinson's disease and MSA. Exidavnemab are a monoclonal antibody (mAb) that selectively targets pathological alpha-synuclein aggregates, while sparing the physiological forms. Aggregated alpha-synuclein damages nerve cells, and by selectively binding and removing these aggregates, exidavnemab is intended to preserve nerve cell function and slow the disease. There is a large unmet medical need for slowing disease progression in diseases such as Parkinson's disease andMSA. Exidavnemib has recently been granted orphan drug designation (ODD) in the US and a positive opinion regarding orphan medicinal product designation (OD) in the EU for the treatment of MSA. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
Price Target Changed • Jun 04Price target decreased by 8.0% to kr289Down from kr314, the current price target is an average from 5 analysts. New target price is 45% above last closing price of kr200. Stock is down 17% over the past year. The company is forecast to post earnings per share of kr11.92 next year compared to a net loss per share of kr2.00 last year.
새로운 내러티브 • Jun 01Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care Regulatory approvals and upcoming diagnostics are set to accelerate Leqembi adoption, expanding access and recurring royalty revenues from an underserved and growing patient base.
분석 기사 • May 29BioArctic's (STO:BIOA B) Solid Profits Have Weak FundamentalsBioArctic AB (publ)'s ( STO:BIOA B ) robust earnings report didn't manage to move the market for its stock. Our...
New Risk • May 21New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
분석 기사 • May 16Here's Why BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation Is The Least Of Shareholders ConcernsKey Insights BioArctic will host its Annual General Meeting on 22nd of May CEO Gunilla Osswald's total compensation...
Price Target Changed • May 07Price target decreased by 9.6% to kr302Down from kr335, the current price target is an average from 5 analysts. New target price is 66% above last closing price of kr182. Stock is down 6.7% over the past year. The company is forecast to post earnings per share of kr10.78 next year compared to a net loss per share of kr2.00 last year.
Reported Earnings • Apr 25Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: kr2.00 loss per share (down from kr2.60 profit in FY 2023). Revenue: kr257.4m (down 58% from FY 2023). Net loss: kr177.1m (down 177% from profit in FY 2023). Products in clinical trials Phase II: 1 Phase III: 1 Post-clinical trial products Approved (during full year): 2 Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings.
공시 • Apr 08BioArctic AB (publ) Presents Data on Exidavnemab and Lecanemab at 2025 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog DisordersBioArctic AB (publ) presented data on exidavnemab and lecanemab at the 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™?), held in Vienna, Austria, April 1-5. BioArctic's partner Eisai also presented new data including results from real-world use of lecanemab. At AD/PD, Dr Johanna Falting, Head of R&D at BioArctic, held an oral presentation on exidavnemab, the company's proprietary drug candidate aimed at treating Parkinson's disease and other alpha-synucleinopathies. In the Phase 1 studies, exidavnemab was generally well tolerated and demonstrated an elimination half-life of approximately 30 days. These properties make exidavnemab a suitable candidate for future studies of disease modification in alpha-synucleinopathyies. The design of the ongoing EXIST Phase 2a study in Parkinson's disease was presented. New data on lecanemab were also presented at the conference. Lecanemab is an anti-amyloid beta (Ab) monoclonal antibody that preferentially binds to toxic protofibrils (soluble Ab aggregates), in addition to targeting and reducing Ab plaques (insoluble Ab aggregates). In an oral presentation by Dr Michael Rosenbloom, University of Washington, USA, recent findings from real-world clinical evidence of lecanemab in the United States were presented. The utilization patterns showed that real-world use of le canemab conforms with the FDA approved prescribing recommendations, and patient adherence suggests that neither MRI monitoring nor possible adverse events significantly interfered with lecanemab dosing. In two other presentations, Dr Lutz Froelich, University of Heidelberg, Germany, presented the efficacy and safety outcomes of lecanemab in early AD apolipoprotein E e4 (ApoEe4) heterozygous carriers and non-carriers in the Phase 3 Clarity AD clinical study. The data presented were forming the basis for the regulatory approval in United Kingdom and the positive CHMP recommendation for EU approval, respectively. The data for the UK and EMA proposed indicated population confirmed that the effects of lecanemab were similar to the overall Clarity AD population with lower risk of ARIA events. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
공시 • Feb 21Bioarctic's Global License Agreement with Bristol Myers Squibb for Pyroglutamate-Amyloid-Beta Antibody Program Effective After Antitrust Clearance and ClosingBioArctic AB (publ) announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-Aß) antibody program to Bristol Myers Squibb. Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million. On December 19, 2024, BioArctic announced that BioArctic had entered into a global license agreement with Bristol Myers Squibb under which Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of BAN1503 and BAN2803 and related products worldwide. The agreement was subject to filing and clearance under U.S. Antitrust legislation (the Hart-Scott-Rodino Antitrust Improvements Act of 1976), a condition which has been fulfilled, and the transaction has now closed. The finalization of the agreement triggers an upfront payment of USD 100 million to BioArctic. The license agreement further includes up to USD 1.25 billion in development, regulatory and commercial milestones, as well as tiered low double-digit royalties on global product sales. BioArctic will retain an option to co-commercialize the products in the Nordic region. BioArctic's PyroGlu-Aß antibody program consists of novel antibodies targeting a specific truncated, pyroglutamate modified form of amyloid-beta. Monomers of PyroGlu-Aß are highly prone to aggregate, leading to the formation of harmful aggregates which cause debilitating cognitive and other symptoms in Alzheimer's disease. The agreement includes both the BAN1503 and BAN2803 antibodies. BAN2803 includes BioArctic'sBrainTransporter™ technology.
Recent Insider Transactions Derivative • Feb 19Insider exercised options to buy kr5.9m worth of stock.On the 13th of February, Johanna Fälting exercised 40.00k options at around kr83.60, then sold 15.00k of them at kr221 each and kept the remainder. Since June 2024, Johanna has owned 44.86k shares directly. Company insiders have collectively sold kr265k more than they bought, via options and on-market transactions in the last 12 months.
분석 기사 • Feb 19Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...
분석 기사 • Feb 18Earnings Beat: BioArctic AB (publ) (STO:BIOA B) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsIt's been a good week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, because the company has just released its...
Reported Earnings • Feb 14Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: kr2.00 loss per share (down from kr2.60 profit in FY 2023). Revenue: kr257.4m (down 58% from FY 2023). Net loss: kr177.1m (down 177% from profit in FY 2023). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
분석 기사 • Jan 31Analysts Just Published A Bright New Outlook For BioArctic AB (publ)'s (STO:BIOA B)Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...
Recent Insider Transactions • Dec 26VP and Head of IR & Communication recently sold kr776k worth of stockOn the 19th of December, Oskar Bosson sold around 3k shares on-market at roughly kr224 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr1.1m more than they bought in the last 12 months.
New Risk • Dec 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
공시 • Dec 05BioArctic AB (publ) Announces Dosing of First Patient in EXIST Phase 2a Study in Parkinson's DiseaseBioArctic AB (publ) announced that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein a-synuclein, believed to play a role in the disease progression in different neurological disorders including Parkinson's disease. The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blind, placebo-controlled study in Parkinson's disease patients to evaluate the safety and tolerability of exidavnemab. The study is conducted in Europe and at least 24 patients will be recruited in, divided into two cohorts of 12 (Cohort 1 and Cohort 2). Participants in Cohort 1 will receive either a lower dose of exidavnemab or placebo and participants in Cohort 2 will receive either a higher dose of exidavnEMab or placebo. In addition to the primary endpoints, a broad range of biomarkers will be evaluated, in plasma, cerebrospinal fluid (CSF) and using digital measurements. Recently, the results of two separate Phase 1 studies of exidavnemab, conducted in collaboration with AbbVie, were published in The Journal of Clinical Pharmacology. The results showed that exidavnemab is generally well-tolerated, with an excellent half-life of approximately 30 days. These data together with the highinity and selectivity toward the pathological aggregated forms of a-synuclein, key to maintaining a high target binding in the brain, laid the foundation for the Phase 2a study.
분석 기사 • Nov 27Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)Celebrations may be in order for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with the analysts delivering a...
Price Target Changed • Nov 20Price target increased by 9.8% to kr321Up from kr292, the current price target is an average from 5 analysts. New target price is 80% above last closing price of kr179. Stock is down 24% over the past year. The company is forecast to post a net loss per share of kr2.69 compared to earnings per share of kr2.60 last year.
Reported Earnings • Nov 15Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: kr0.22 loss per share (down from kr1.42 profit in 3Q 2023). Revenue: kr76.6m (down 63% from 3Q 2023). Net loss: kr19.6m (down 116% from profit in 3Q 2023). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 56%. Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 14% per year.
공시 • Nov 15Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EUBioArctic AB (publ) announced that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization application (MAA) for lecanemab as treatment of Alzheimer's disease. The recommendation applies to the treatment of early Alzheimer's disease in adult patients that are apolipoprotein E e4 (ApoE e4) heterozygotes or non-carriers. The CHMP recommendation for the European Commission to approve lecanemab follows Eisai's request for a re-examination of the CHMP's earlier negative recommendation. A decision from the European Commission is expected within 67 days. The CHMP recommends approval of lecanemab for the treatment of mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease, in adult patients who are heterozygotes (carry one copy) or are non-carriers of the Apolipoprotein E e4 (ApoE e4) gene. Lecanemab is already approved in the US, Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, and the Great Britain. Eisai is responsible for the clinical development, applications for market approval and commercialization of lecanemab for Alzheimer's disease. BioArctic has the rights to commercialize lecanemab in the Nordic region. Currently, BioArctic and Eisai are preparing for joint commercialization in these countries, pending approval from the European Commission.
공시 • Nov 14+ 3 more updatesBioArctic AB (publ) to Report Q2, 2025 Results on Aug 28, 2025BioArctic AB (publ) announced that they will report Q2, 2025 results on Aug 28, 2025
공시 • Oct 13BioArctic AB (publ) Presents Nomination CommitteePursuant to the instruction regarding the appointment of the Nomination Committee BioArctic AB’s (publ) shall have a Nomination Committee comprising one representative for each of the three principal shareholders in terms of votes, based on the information received from Euroclear Sweden AB on the last banking day in September 2024, as well as the Chairman of the Board (convener). September 30, 2024, the three largest shareholders were Demban AB, Ackelsta AB and The Fourth Swedish National Fund (Fjärde AP-fonden). The three owners who have agreed to be part of the Nomination Committee, Demban AB, Ackelsta AB and Fjärde AP-fonden, represent approx. 61% of the shares and approx. 84% of the votes in the company. The nomination committee comprises the following members: Margareta Öhrvall, appointed by Demban AB, Claes Andersson, appointed by Ackelsta AB, Jannis Kitsakis, chairperson of the Nomination Committee appointed by Fjärde AP-fonden. The Nomination Committee shall prepare proposals for the 2025 Annual General Meeting regarding the Chairman of the Meeting, number of Board members, fees to be paid to the Chairman of the Board and Board members, election of Board members and Board Chairman, remuneration to the auditor and election of auditor and, if necessary, proposal for changes in the instruction to the Nomination Committee.
공시 • Oct 12BioArctic AB (publ), Annual General Meeting, May 22, 2025BioArctic AB (publ), Annual General Meeting, May 22, 2025, at 16:30 W. Europe Standard Time. Location: stockholm Sweden
Recent Insider Transactions Derivative • Sep 16Vice President of Human Resources exercised options and sold kr454k worth of stockOn the 12th of September, Gunilla Andersson exercised 5k options at a strike price of around kr83.10 and sold these shares for an average price of kr174 per share. This trade did not impact their existing holding. As of today, Gunilla currently holds no shares directly. Company insiders have collectively sold kr68k more than they bought, via options and on-market transactions in the last 12 months.
분석 기사 • Sep 01BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportA week ago, BioArctic AB (publ) ( STO:BIOA B ) came out with a strong set of quarterly numbers that could potentially...
Price Target Changed • Aug 30Price target decreased by 9.3% to kr291Down from kr320, the current price target is an average from 5 analysts. New target price is 75% above last closing price of kr167. Stock is down 47% over the past year. The company is forecast to post a net loss per share of kr1.13 compared to earnings per share of kr2.60 last year.
Reported Earnings • Aug 30Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: kr0.77 loss per share (improved from kr1.16 loss in 2Q 2023). Revenue: kr50.4m (up kr47.7m from 2Q 2023). Net loss: kr68.4m (loss narrowed 33% from 2Q 2023). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
공시 • Aug 27BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical PharmacologyBioArctic AB (publ) announced that the results from two phase-1 studies with exidavnemab have been published in The Journal of Clinical Pharmacology. Exidavnemab is a drug candidate under development aimed at treating diseases such as Parkinson's disease. It is a monoclonal antibody designed to target aggregated forms of the protein -synuclein, while sparing the physiological form of the protein. In two separate phase 1 clinical studies conducted in collaboration with AbbVie, exidavnemab was tested on healthy volunteers to assess the safety, tolerability and pharmacokinetics of the candidate drug. The studies included 98 participants from different ethnic backgrounds, of which 85 received exidavnemab, either as an intravenous dose ranging from 100 to 6000 mg or a subcutaneous dose of 300 mg. The results showed that exidavnemab was generally well-tolerated. with an excellent half-life of approximately 30 days. This together with the high affinity and selectivity toward the pathological aggregated forms of -synuclein is key to maintain a high target binding in the brain.
분석 기사 • Aug 15Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024The analysts covering BioArctic AB (publ) ( STO:BIOA B ) delivered a dose of negativity to shareholders today, by...
Price Target Changed • Jul 30Price target decreased by 8.6% to kr336Down from kr368, the current price target is an average from 5 analysts. New target price is 114% above last closing price of kr157. Stock is down 47% over the past year. The company is forecast to post a net loss per share of kr0.22 compared to earnings per share of kr2.60 last year.
New Risk • Jul 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Lotta Ljungqvist was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Recent Insider Transactions • May 27Insider recently sold kr710k worth of stockOn the 24th of May, Johanna Fälting sold around 3k shares on-market at roughly kr237 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr3.4m more than they bought in the last 12 months.
공시 • May 25BioArctic AB (publ) Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South KoreaBioArctic AB (publ) announced that the Ministry of Food and Drug Safety (MFDS) in South Korea published that Leqembi® (lecanemab) has been approved for treatment in patients with mild cognitive impairment due to Alzheimer's disease (AD) and mild AD (early AD).
Reported Earnings • May 19First quarter 2024 earnings: Revenues exceed analyst expectationsFirst quarter 2024 results: Revenue: kr29.6m (down 93% from 1Q 2023). Net loss: kr57.6m (down 120% from profit in 1Q 2023). Revenue exceeded analyst estimates by 63%. Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 21Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: EPS: kr2.60 (up from kr0.13 loss in FY 2022). Revenue: kr616.0m (up 169% from FY 2022). Net income: kr229.2m (up kr240.4m from FY 2022). Profit margin: 37% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Products in clinical trials Phase I: 2 Phase III: 1 Post-clinical trial products Pre-registration: 1 Approved (during full year): 1 Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 24%. Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
분석 기사 • Apr 13Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)With a price-to-sales (or "P/S") ratio of 30.5x BioArctic AB (publ) ( STO:BIOA B ) may be sending very bearish signals...
공시 • Mar 14BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersBioArctic AB (publ) and its partner Eisai presented new data on lecanemab (brand name: Leqembi) at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD), held in Lisbon, Portugal and virtually, March 5-9. BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aß) antibody lecanemab and other anti Aß antibodies. Lecanemab was designed to preferentially bind soluble (protofibrils), as well as insoluble Aß aggregates (fibrils), to reduce both Aß protofibrils and Aß plaques in the brain. The difference in binding to CAA was presented, with lecanemab having lower binding to CAA than most other antibodies. This could explain the difference in the adverse event ARIA seen between different antibodies, with lecanemab showing relatively low incidence of ARIA. In another presentation Professor Christopher van Dyke presented extended efficacy results from the Phase 3 Clarity AD open label extension study of lecanemab in Alzheimer's disease up to 30 months, showing continued benefit with lecanemab treatment. Professor van Dyke also highlighted data from the tau sub-study of Clarity AD, which showed that all cohorts of the tau population benefitted from treatment with lecanemab. Data from the low tau population, representing earlier stages of the disease, indicated that intervening in early stages of disease may be particularly impactful in stabilizing the disease process. Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and the anti Aß protofibril antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for commercialization in the region.
Major Estimate Revision • Mar 10Consensus EPS estimates increase by 112%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from kr494.3m to kr502.5m. EPS estimate increased from kr0.094 to kr0.199 per share. Net income forecast to shrink 93% next year vs 14% growth forecast for Biotechs industry in Sweden . Consensus price target broadly unchanged at kr366. Share price rose 6.4% to kr233 over the past week.
Recent Insider Transactions Derivative • Feb 21Vice President of Human Resources exercised options to buy kr1.2m worth of stock.On the 18th of February, Gunilla Andersson exercised options to buy 5k shares at a strike price of around kr83.60, costing a total of kr418k. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. As of today, Gunilla currently holds no shares directly. Company insiders have collectively sold kr1.9m more than they bought, via options and on-market transactions in the last 12 months.
분석 기사 • Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under ThreatThe latest analyst coverage could presage a bad day for BioArctic AB (publ) ( STO:BIOA B ), with the analysts making...
Reported Earnings • Feb 18Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: EPS: kr2.60 (up from kr0.13 loss in FY 2022). Revenue: kr620.1m (up 170% from FY 2022). Net income: kr229.2m (up kr240.4m from FY 2022). Profit margin: 37% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Products in clinical trials Phase I: 1 Phase III: 1 Post-clinical trial products Approved (during full year): 1 Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 24%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
Major Estimate Revision • Feb 16Consensus revenue estimates fall by 15%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr595.9m to kr509.3m. EPS estimate fell from kr1.83 to kr0.352 per share. Net income forecast to shrink 73% next year vs 16% growth forecast for Biotechs industry in Sweden . Consensus price target broadly unchanged at kr374. Share price rose 8.3% to kr228 over the past week.
분석 기사 • Feb 03News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under ThreatThe analysts covering BioArctic AB (publ) ( STO:BIOA B ) delivered a dose of negativity to shareholders today, by...
공시 • Jan 11+ 1 more updateThe European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemabBioArctic AB's (publ) announced that the Scientific Advisory Group (SAG) will convene to discuss the Marketing Authorisation Application (MAA) of lecanemab (generic name, brand name: Leqembi®), which is currently under review by the European Medicines Agency (EMA). The meeting of the SAG is expected to take place during the first quarter of 2024. The SAG is convened at the request of the Committee for Medicinal Products for Human Use (CHMP) of the EMA to provide independent advice on scientific or technical matters relating to products under evaluation by the CHMP, or on other scientific issues relevant to the work of the CHMP. It is a commonly used procedure for new treatments and new treatment concepts. Eisai expects the European Commission's decision for the MAA of lecanemab in the second quarter of 2024, if the opinion from the CHMP is received by March 31, 2024, following discussion by the SAG. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region.
분석 기사 • Dec 23Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) RevenuesBioArctic AB (publ)'s ( STO:BIOA B ) price-to-sales (or "P/S") ratio of 39.1x might make it look like a strong sell...
Major Estimate Revision • Nov 21Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr627.2m to kr527.9m. EPS estimate fell from kr2.85 to kr1.89 per share. Net income forecast to shrink 14% next year vs 12% growth forecast for Biotechs industry in Sweden . Consensus price target broadly unchanged at kr372. Share price rose 3.3% to kr234 over the past week.
Major Estimate Revision • Nov 15Consensus revenue estimates fall by 14%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr729.8m to kr627.1m. EPS estimate fell from kr3.45 to kr2.84 per share. Net income forecast to shrink 1.5% next year vs 30% growth forecast for Biotechs industry in Sweden . Consensus price target down from kr392 to kr372. Share price rose 4.5% to kr223 over the past week.
